Smoking cessation treatment in a real
This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Rovina, N. Articles by Gratziou, C. Search for Related Content PubMed PubMed Citation Articles by Rovina, N. Articles by Gratziou, C. Social Bookmarking What’s this? Smoking cessation treatment in a real-life setting: the Greek experience Nikoletta Rovina
Smoking Cessation Clinic, Pulmonary and Critical Care Department, Evgenidion Hospital, 20 Papadiamantopoulou Str., 11528, Athens, Greece, rovinanikoletta{at}hotmail.com
Ioanna Nikoloutsou
Smoking Cessation Clinic, Department of Pulmonary and Critical Care Medicine, Evgenidio Hospital, University of Athens, Greece
Efi Dima
Smoking Cessation Clinic, Department of Pulmonary and Critical Care Medicine, Evgenidio Hospital, University of Athens, Greece
Makrina Michailidou
Smoking Cessation Clinic, Department of Pulmonary and Critical Care Medicine, Evgenidio Hospital, University of Athens, Greece
Charalampos Roussos
Smoking Cessation Clinic, Department of Pulmonary and Critical Care Medicine, Evgenidio Hospital, University of Athens, Greece, Department of Critical Care and Pulmonary Services, “Evangelismos” Hospital, University of Athens
Christina Gratziou
Smoking Cessation Clinic, Department of Pulmonary and Critical Care Medicine, Evgenidio Hospital, University of Athens, Greece
Objectives: The aim of this study was to estimate the clinical efficacy of counseling combined with currently used pharmacotherapy for smoking cessation (bupropion SR and nicotine replacement therapy, NRT) in actual clinical practice, and to identify predictors of successful abstinence at the end of therapy, as well as predictors of sustained abstinence in one year.
Methods: 895 smokers, self—motivated to quit, received bupropion SR for 7 or 19 weeks and/or nicotine replacement therapy (NRT) (nicotine patch) for 9 weeks in combination with individual behavioural therapy. An intensive program including repetitive visits and telephone contacts during treatment and one year’s follow-up period was available for supporting and motivating smokers to prevent relapse.
Results: Post-treatment abstinence rates were 71.6% and 53.2% in bupropion SR groups for 7 and 19 weeks of treatment, respectively, (p < 0.001), 63.4% in bupropion SR plus nicotine patch group and 45% (p < 0.001) in nicotine patch group. One year's follow-up abstinence rates were 43.1%, 29.6%, 30.4% and 18.4% (p < 0.05), respectively. Predictors of successful abstinence at the end of therapy included (a) bupropion SR, (b) lower DSM IV symptom score, and (c) lower nicotine addiction, while predictors for sustained abstinence in one year included: (a) bupropion SR, (b) lower nicotine addiction, and (c) smoker's motivation.
Conclusions: Smoking cessation interventions implementing intensive multi-component programs and constant smokers’ motivation in health care settings of actual practice seem promising for increasing short and long-term abstinence rates.
Key Words: smoking cessation • abstinence • intensive intervention • actual clinical practice • motivation
Therapeutic Advances in Respiratory Disease, Vol. 1, No. 2, 93-104 (2007) DOI: 10.1177/1753465807085799
CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati Twitter What’s this?
This article has been cited by other articles:
N. Rovina, I. Nikoloutsou, G. Katsani, E. Dima, K. Fransis, C. Roussos, and C. GratziouEffectiveness of pharmacotherapy and behavioral interventions for smoking cessation in actual clinical practice Therapeutic Advances in Respiratory Disease, December 1, 2009; 3(6): 279 – 287.[Abstract] [PDF]
Incoming search terms for the article:
Similar articles
- – Ng et al. 6 (2): 125 -
This Article Full Text (PDF) All Versions of this Article:1742395310364253v1 6/2/125 most recent References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a ... - Quit Smoking Shot
Have you ever tried to stop smoking? You must have experienced severe pain and different kinds of side effects. It is because you are not getting enough nicotine and suffering from severe pain and different types of side effects. The SMARTTM Shot has been introduced to help you quit smoking. ... - Latino smokers in the Northeast United States -
Health Education Research Advance Access published online on March 17, 2010 Health Education Research, doi:10.1093/her/cyq010 This Article Full Text Full Text (PDF) E-letters: Submit a response Alert me when this article is cited Alert me when E-letters are posted Alert me ... - Quit Smoking Shot
The two medicines involved in a new stop smoking shot – the SMARTTM Shot – has been around for about ten years, Scopolamine and Atarax, and are now FDA approved for stop smoking aids. SMART stands for Scopolamine Medicated Anticholinergic Receptor Treatment, with Scopolamine as a medicine that contains the ingredient of the seasickness patch, ... - Zyban Bupropion as a Quit Smoking Aid
What is Zyban? Zyban and Wellbutrin are both brand names for the generic drug, bupropion hydrochloride. While bupropion is not for everyone, it does have the advantage of lessening the discomforts associated with nicotine withdrawal. This can make cessation much more manageable for those people who haven’t been able to successfully quit smoking ...

Twitter